AgaMatrix, Inc.: Series C $23.7M

AgaMatrix (Salem, NH) maker of blood glucose monitoring systems that provide results to help users better manage their diabetes closed a $23.7M Series C financing. Participants include Ferrer Freeman & Co.

AmpliMed Corp.: Series C $22.0M

AmpliMed (Tucson, AZ) a clinical-stage pharmaceutical company with Phase II lead compounds for malignant melanoma and pancreatic cancer closed on $5M traunche of a $22M Series C financing. Participants include BioMed Venture Partners, Biotech Insight Ventures, Solstice Capital and Valley Ventures.

Aerovance, Inc.: Series C $60M

Aerovance (Berkeley, CA) a biopharmaceutical company focused on the development asthma, cystic fibrosis and chronic obstructive pulmonary disease has closed a $60M Series C. Participants in the round included Apax Partners, Clarus Ventures, Alta Partners, Lehman Brothers, NGN Capital and Burrill & CO.

Endocyte, Inc.: Series C $15M

Endocyte (West Lafayette, IN) developer of folate-targeted based therapeutics for the treatment of renal cell carcinoma, ovarian, endometrial and nscl cancer raised $15M in a Series C financing. Participants included Sanderling Ventures, Burrill & Company, Triathlon Medical Ventures, Blue Chip Venture Company, American Bailey Ventures and CID Capital.

Regado Biosciences, Inc.: Series C $23M

Regado Biosciences (Durham, NC) a biopharmaceutical company with a platform oligonucleotide drug-antidote pairing system focused upon the anticoagulant market has closed a $23M Series C financing. The deal was led by Caxton Advantage Life Sciences, Domain Associates, Quaker BioVentures and Aurora Funds.

CoreValve, Inc.: Series C Series C $33M

CoreValve (Irvine, CA) is a medical device company introducing a percutaneous revalving system to replace failing aortic heart valves without surgical access closed a $33M Series C financing. The deal was led by Maverick Capital other participants included Apax Partners, HealthCap and Sofinnova Partners.

Phenomix Corp.: Series C $55M

Phenomix (San Diego, Calif.) a drug discovery and development company focused on the treatment of Type 2 diabetes and hepatitis C raised a $55M Series C financing. The deal was led by Nomura Phase4 and joined by JPMorgan, Delphi Ventures, Baker Brothers, Alta Partners, Sofinnova Ventures, Bay City Capital, CMEA Ventures, Novartis Venture Fund and GBS Venture Partners.

Transoma Medical, Inc.: Series C $13M

Transoma Medical (St. Paul, MN) maker of implantable wireless monitoring systems for patients with chronic cardiovascular disease closed a $13M Series C financing. The deal was led by Canaan Partners, Affinity Capital Management and Polaris Venture Partners.

Advanced BioHealing, Inc.: Series C $25.5M

Advanced BioHealing (La Jolla, CA) a regenerative medicine, artificial skin tissue and wound healing company raised $25.5M in Series C funding.The deal was led by Safeguard Scientific and was accompanied by Channel Medical Partners, Red Abbey Venture Partners, Canaan Partners and Wheatley Partners.

Cara Therapeutics, Inc.: Series C $24M

Cara Therapeutics (Tarrytown, NY) is an emerging biotechnology company focused on developing novel therapeutics to treat human diseases associated with pain and inflammation has closed a $24M Series C financing. Investors included Scottish Widows Investment Partnership, Mitsubishi International Corporation, MVM Life Science Partners, Alta Partners and Ascent Biomedical Ventures.